Author

I. R. Judson

Observed names: I Judson, I R Judson, I. Judson, I.R. Judson, IR Judson, Ian Judson, JUDSON, IR, Judson, I, Judson, IR

Institution: Fondazione IRCCS Istituto Nazionale dei Tumori

Observed institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Keio University, Beatson West of Scotland Cancer Centre, Charing Cross Hospital, Johnson Matthey (United Kingdom), Royal Marsden Hospital, The Christie Hospital, Addenbrooke's Hospital, Fondazione IRCCS Istituto Nazionale dei Tumori, Newcastle University

OpenAlex ID: A5000658269

An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)

2017 · B. Kasper, C. Baumgarten, et al. · Annals of Oncology · 420

PDF

ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.

1991 · A L Jackman, G A Taylor, et al. · PubMed · 357

Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.

1993 · H Calvert, I Judson, et al. · PubMed · 80

Idoxifene: report of a phase I study in patients with metastatic breast cancer.

1995 · R C Coombes, B P Haynes, et al. · PubMed · 70

Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.

1991 · D C Talbot, I E Smith, et al. · Journal of Clinical Oncology · 61

A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer

1991 · TJ Powles, AL Jones, et al. · British Journal of Cancer · 34

PDF

Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717)

1987 · Alan Calvert, David Newell, et al. · PubMed · 29

The contemporary drug development process: advances and challenges in preclinical and clinical development.

2003 · Michelle D Garrett, Mike I Walton, et al. · PubMed · 26

Metabolites of 2'-fluoro-2'-deoxy-D-glucose detected by 19F magnetic resonance spectroscopy in vivo predict response of murine RIF-1 tumors to 5-fluorouracil.

2000 · P M McSheehy, M O Leach, et al. · PubMed · 25

73 POSTER Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients

2006 · P. Stopfer, W. Roth, et al. · European Journal of Cancer Supplements · 17

Preclinical evaluation and phase I trials

1992 · I. R. Judson · Cancer biology and medicine · 17

A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies

2005 · C. P. Lee, G. Attard, et al. · Journal of Clinical Oncology · 15

A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours

2008 · E. R. Plummer, H. Calvert, et al. · Journal of Clinical Oncology · 14

ZD9331: discovery to clinical development

2004 · T. S. Benepal, I. Judson · Anti-Cancer Drugs · 14

Phase II trial of trimelamol in refractory ovarian cancer

1991 · IR Judson, AH Calvert, et al. · British Journal of Cancer · 14

Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase inhibitor given as a 5-day continuous infusion every 3 weeks

1999 · J. Trigo, C. Rees, et al. · European Journal of Cancer · 12

Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro[2-methylpyridine] platinum[II])

2000 · L Kelland, I Judson, et al. · Lung Cancer · 10

Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks

1999 · R. Plummer, C. Rees, et al. · European Journal of Cancer · 9

Frey’s syndrome after cisplatin-based chemotherapy for testicular teratoma

1998 · P. Beale, J. Filshie, et al. · Annals of Oncology · 9

A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98

2005 · L. Vidal, M. Leslie, et al. · Journal of Clinical Oncology · 6

Resolution of High-Output Cardiac Failure Following Treatment of Multiple Myeloma

1989 · I R Judson, M E Gore, et al. · New England Journal of Medicine · 4

Clinical benefit in phase I trials of novel molecularly targeted agents: Does dose matter?

2008 · S. C. Postel-Vinay, H. Arkenau, et al. · Journal of Clinical Oncology · 3

CHIR-258: first-in-human phase 1 dose escalating trial of an oral, selectively targeted tyrosine kinase inhibitor in patients with solid tumors

2005 · D. Sarker, J. Evans, et al. · Journal of Clinical Oncology · 3

The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenografts.

1996 · H M Coley, M Jarman, et al. · PubMed · 3

443 Decreased expression of DNMT1 at the mRNA level following 7 day infusion of the antisense compound MG98 in a phase I study

2004 · M. Leslie, S.A. Coulthard, et al. · European Journal of Cancer Supplements · 2

Works count: 56

Citation count: 1,271

H-index: 14

I10-index: 17